November 20, 2025 — Leads & Copy —
Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) has completed a non-brokered private placement, raising $600,000 CAD through the issuance of 576,923 common shares at $1.04 per share. The offering, which closed Nov. 19, 2025, was increased from the originally announced $500,000 CAD.
The proceeds will support general working capital and operating expenses not covered by the company’s human trial funding grants.
The private placement involved the issuance of 480,923 common shares to an officer of the Company, a related party. According to Multilateral Instrument 61-101, this transaction is exempt from formal valuation and minority shareholder approval requirements because the fair market value of the distributed shares and the consideration received does not exceed 25% of the company’s market capitalization.
All common shares issued are subject to a four-month hold period plus one day from the closing date. No finders’ fees were paid in connection with the offering.
Arch Biopartners Inc. is focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD). Its pipeline includes:
- LSALT peptide: Phase II trial for cardiac surgery-associated AKI.
- Cilastatin: Phase II trial for toxin-induced AKI.
- CKD Therapeutics: Pre-clinical program for chronic kidney disease.
These treatments address unmet needs in kidney care, targeting both chronic and acute indications affecting over 800 million patients.
Arch Biopartners Inc. has 66,933,289 common shares outstanding.
Aaron Benson, Director of Communications, can be contacted at 647-428-7031 for more information.
More information about Arch Biopartners’ science and ongoing clinical trials is available at: www.archbiopartners.com/our-science
Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news.
Aaron Benson
Director of Communications
Arch Biopartners, Inc.
647-428-7031
Send a message or subscribe for email alerts at: www.archbiopartners.com/contact-us
Source: Arch Biopartners Inc.
